Literature DB >> 20959375

Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: initial results.

T A Heusner1, S Hahn, C Jonkmanns, S Kuemmel, F Otterbach, M E Hamami, A R Stahl, A Bockisch, M Forsting, G Antoch.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the diagnostic accuracy of fused fluoro-deoxy-D-glucose positron emission tomography/magnetic resonance mammography (FDG-PET/MRM) in breast cancer patients and to compare FDG-PET/MRM with MRM.
METHODS: 27 breast cancer patients (mean age 58.9±9.9 years) underwent MRM and prone FDG-PET. Images were fused software-based to FDG-PET/MRM images. Histopathology served as the reference standard to define the following parameters for both MRM and FDG-PET/MRM: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for the detection of breast cancer lesions. Furthermore, the number of patients with correctly determined lesion focality was assessed. Differences between both modalities were assessed by McNemaŕs test (p<0.05). The number of patients in whom FDG-PET/MRM would have changed the surgical approach was determined.
RESULTS: 58 breast lesions were evaluated. The sensitivity, specificity, PPV, NPV and accuracy were 93%, 60%, 87%, 75% and 85% for MRM, respectively. For FDG-PET/MRM they were 88%, 73%, 90%, 69% and 92%, respectively. FDG-PET/MRM was as accurate for lesion detection (p = 1) and determination of the lesions' focality (p = 0.7722) as MRM. In only 1 patient FDG-PET/MRM would have changed the surgical treatment.
CONCLUSION: FDG-PET/MRM is as accurate as MRM for the evaluation of local breast cancer. FDG-PET/MRM defines the tumours' focality as accurately as MRM and may have an impact on the surgical treatment in only a small portion of patients. Based on these results, FDG-PET/MRM cannot be recommended as an adjunct or alternative to MRM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959375      PMCID: PMC3473854          DOI: 10.1259/bjr/93330765

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  42 in total

1.  MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data.

Authors:  Thomas Beyer; Markus Weigert; Harald H Quick; Uwe Pietrzyk; Florian Vogt; Christoph Palm; Gerald Antoch; Stefan P Müller; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-19       Impact factor: 9.236

Review 2.  PET/MRI hybrid imaging: devices and initial results.

Authors:  Bernd J Pichler; Martin S Judenhofer; Hans F Wehrl
Journal:  Eur Radiol       Date:  2008-03-21       Impact factor: 5.315

Review 3.  [Breast MR imaging: validated indications and unsolved problems].

Authors:  Sophie Taïeb; Luc Ceugnart
Journal:  Bull Cancer       Date:  2008-01       Impact factor: 1.276

Review 4.  Multimodal imaging approaches: PET/CT and PET/MRI.

Authors:  Bernd J Pichler; Martin S Judenhofer; Christina Pfannenberg
Journal:  Handb Exp Pharmacol       Date:  2008

Review 5.  Trends in breast cancer screening and diagnosis.

Authors:  Alice Rim; Melanie Chellman-Jeffers
Journal:  Cleve Clin J Med       Date:  2008-03       Impact factor: 2.321

Review 6.  Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging?

Authors:  Bernd J Pichler; Hans F Wehrl; Armin Kolb; Martin S Judenhofer
Journal:  Semin Nucl Med       Date:  2008-05       Impact factor: 4.446

Review 7.  Role of MRI in screening, diagnosis and management of breast cancer.

Authors:  Anil Kumar Swayampakula; Charlotte Dillis; Jame Abraham
Journal:  Expert Rev Anticancer Ther       Date:  2008-05       Impact factor: 4.512

Review 8.  Overview of breast cancer staging and surgical treatment options.

Authors:  Clarisa Hammer; Alicia Fanning; Joseph Crowe
Journal:  Cleve Clin J Med       Date:  2008-03       Impact factor: 2.321

Review 9.  [Magnetic resonance imaging in preoperative staging for breast cancer: pros and contras].

Authors:  C K Kuhl; M Braun
Journal:  Radiologe       Date:  2008-04       Impact factor: 0.635

10.  Breast cancer staging in a single session: whole-body PET/CT mammography.

Authors:  Till A Heusner; Sherko Kuemmel; Lale Umutlu; Angela Koeninger; Lutz S Freudenberg; Elke A M Hauth; Klaus R Kimmig; Michael Forsting; Andreas Bockisch; Gerald Antoch
Journal:  J Nucl Med       Date:  2008-07-16       Impact factor: 10.057

View more
  6 in total

1.  Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Authors:  C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-06       Impact factor: 9.236

2.  Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing 18F-FDG-PET/MRI.

Authors:  Julian Kirchner; Johannes Grueneisen; Ole Martin; Mark Oehmigen; Harald H Quick; Ann-Kathrin Bittner; Oliver Hoffmann; Marc Ingenwerth; Onofrio Antonio Catalano; Philipp Heusch; Christian Buchbender; Michael Forsting; Gerald Antoch; Ken Herrmann; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-28       Impact factor: 9.236

Review 3.  Breast PET/MR Imaging.

Authors:  Amy Melsaether; Linda Moy
Journal:  Radiol Clin North Am       Date:  2017-02-01       Impact factor: 2.303

4.  Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study.

Authors:  Matthew D Blackledge; David J Collins; Nina Tunariu; Matthew R Orton; Anwar R Padhani; Martin O Leach; Dow-Mu Koh
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

Review 5.  The application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part II. Diagnosis after treatment initiation, future perspectives.

Authors:  Elżbieta Jodłowska; Rafał Czepczyński; Agata Czarnywojtek; Amanda Rewers; Grażyna Jarząbek; Witold Kędzia; Marek Ruchała
Journal:  Contemp Oncol (Pozn)       Date:  2016-08-04

6.  Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease.

Authors:  Matthew D Blackledge; Nina Tunariu; Matthew R Orton; Anwar R Padhani; David J Collins; Martin O Leach; Dow-Mu Koh
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.